Erratum: MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2 (Molecular Cancer Therapeutics (2017) 16 (739–751) DOI: 10.1158/1535-7163.MCT-16-0591);MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2

Molecular Cancer Therapeutics

Volumn 16, Issue 4, 2017, Pages 739-751

  Li, Peilong ^a   Zhang, Xin ^a   Wang, Haiyan ^b   Wang, Lili ^a   Liu, Tong ^a   Du, Lutao ^a   Yang, Yongmei ^a   Wang, Chuanxin ^c  

^a SHANDONG UNIVERSITY   (China)

^b Women and Children s Hospital of LinYi City   (China)

^c THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN G ANTIBODY; LONG UNTRANSLATED RNA; MESSENGER RNA; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1; OXALIPLATIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; 3' UNTRANSLATED REGION; EZH2 PROTEIN, HUMAN; MALAT1 LONG NON-CODING RNA, HUMAN; MICRORNA; MIRN218 MICRORNA, HUMAN; PLATINUM COMPLEX;

AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CHEMOSENSITIVITY; CLINICAL FEATURE; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; METASTASIS; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN RNA BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TUMOR CLASSIFICATION; 3' UNTRANSLATED REGION; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HT-29 CELL LINE; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; MICRORNAS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RNA, LONG NONCODING; SURVIVAL ANALYSIS;

EID: 85016946354     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-20-1028     Document Type: Erratum

References (39)

1. Han D, Wang M, Ma N, Xu Y, Jiang YT, Gao X. Long noncoding RNAs: novel players in colorectal cancer. Cancer Lett 2015;361:13-21.
2. Li PL, Zhang X, Wang LL, Du LT, Yang YM, Li J, et al. MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5. Carcinogenesis 2015;36: 1484-93.
3. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Cancer Res 2006;12:4147-53.
4. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II Study. J Clin Oncol 2005;23: 9243-9.
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
6. Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H, et al. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res 2008;68: 516-20.
7. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, et al. Twist1-mediated adriamycin induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells.Clin Cancer Res 2009;15:2657-65.
8. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009;136:629-41.
9. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett 2013;339:159-66.
10. Ji P, Diederichs S,WangW, Boing S, Metzger R, Schneider PM, et al.MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003;22: 8031-41.
11. Yang L, Lin C, Liu W, Zhang J, Ohgi KA, Grinstein JD, et al. ncRNA-and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell 2011;147:773-88.
12. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. TGF-b-induced upregulation ofmalat1 promotes bladder cancermetastasis by associating with suz12. Clin Cancer Res 2014;20:1531-41.
13. Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res 2015; 75:1322-31.
14. Qi Y, Ooi HS, Wu J, Chen J, Zhang X, Tan S, et al. MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10. Oncotarget 2016;7:12693-703.
15. Ji Q, Liu X, Fu X, Zhang L, SuiH, Zhou L, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/b-catenin signal pathway. PLoS One 2013;8:e78700.
16. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long non-coding RNA and its important 30 end functional motif in colorectal cancer metastasis. Int J Oncol 2011;39:169-75.
17. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of Ecadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008;27:7274-84.
18. Liu YL, Gao X, Jiang Y, Zhang G, Sun ZC, Cui BB, et al. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. J Cancer Res Clin Oncol 2015;141:661-9.
19. Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett 2013;333:213-21.
20. Zhang X, Yang X, Zhang Y, Liu X, Zheng G, Yang Y, et al. Direct serum assay for cell free Bmi-1 mRNA and its potential diagnostic and prognostic value for colorectal cancer. Clin Cancer Res 2015;21:1225-33.
21. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay formicroRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011;57:84-91.
22. Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, et al. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration resistant prostate cancer. Oncotarget 2015;6:41045-55.
23. Jeggari A, Marks DS, Larsson E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics 2012; 28:2062-3.
24. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G2nd, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009;69:1951-7.
25. Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, et al. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br J Cancer 2014;111:736-48.
26. Hu ZY, Wang XY, Guo WB, Xie LY, Huang YQ, Liu YP, et al. Long noncoding RNA MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in colorectal cancer cells. Oncotarget 2016; 7:11733-43.
27. Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol 2014;7:3174-81.
28. Zhang X, Zhang Y, Liu X, Fang A, Wang J, Yang Y, et al. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer. Oncotarget 2016;7: 3255-66.
29. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature 2012;489:101-8.
30. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010;464:1071-6.
31. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
32. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011;146:353-8.
33. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: Decoding miRNAceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 2014;42:D92-7.
34. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014;505:344-52.
35. Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer 2014;13:92.
36. Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y, et al. MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. J Urol 2013;190:1059-68.
37. He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, et al. MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med 2013;18: 1491-8.
38. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
39. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.